TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21726125

Group type: EXPERIMENTAL
Intervention: High-risk subjects by FINRISK and SCORE models
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-risk subjects by FINRISK at the extrapolated age of 60
Number of subjects: 120

Group type: COMPARATOR
Intervention: Number of MetS variables
Number of subjects: 120
Study: 21726849

Group type: EXPERIMENTAL
Intervention: DMEK with stromal gap or partial graft detachment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DMEK with normal visual potential
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DMEK with upside-down graft
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Descemet graft implantation without endothelial graft
Number of subjects: 150
Study: 21726862

Group type: EXPERIMENTAL
Intervention: Inter-adventitial diameter (IAD)
Number of subjects: 5641

Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LV mass)
Number of subjects: 5641

Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LV mass) for women
Number of subjects: 5641

Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LV mass) for men
Number of subjects: 5641
Study: 21727108

Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Number of subjects: 286
Study: 21728727

Group type: EXPERIMENTAL
Intervention: Superion® Interspinous Spacer (Vertiflex, Inc., CA, USA)
Number of subjects: 0
Study: 21729182

Group type: EXPERIMENTAL
Intervention: Inhaled dust mite allergen challenge (Dermatophagoides farinae extract; PD(max) = fall in forced expiratory volume in 1 s of 10%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled dust mite allergen challenge
Number of subjects: 12

Group type: COMPARATOR
Intervention: No allergen challenge (baseline)
Number of subjects: 12
Study: 21729732

Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine
Number of subjects: 89
Study: 21730256

Group type: EXPERIMENTAL
Intervention: Localized aggressive periodontitis (LAP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy sites
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LAP plasma
Number of subjects: 53
Study: 21730273

Group type: EXPERIMENTAL
Intervention: Repeat CT scans performed within 15 minutes
Number of subjects: 0
Study: 21731830

Group type: EXPERIMENTAL
Intervention: PHQ-9 suicide screening item
Number of subjects: 166

Group type: COMPARATOR
Intervention: Structured Clinical Interview for DSM-IV (SCID-I mood module)
Number of subjects: 166
Study: 21731831

Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/d; target of 5, 10, or 15 mg/d)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 21731833

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1092
Study: 21731825

Group type: EXPERIMENTAL
Intervention: Smoking (light smokers <20 cigarettes/day)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Smoking (heavy smokers ≥20 cigarettes/day)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Smokers (overall)
Number of subjects: 784
Study: 21732212

Group type: EXPERIMENTAL
Intervention: Daily self-weighing
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Monthly self-weighing
Number of subjects: 1222
Study: 21732836

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Number of subjects: 398

Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Confirmed pulmonary hypertension
Number of subjects: 398
Study: 21733227

Group type: EXPERIMENTAL
Intervention: OROS-MPH treatment for 12 weeks
Number of subjects: 102
Study: 21733476

Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking scale - Clinician Rating (CHRT-C)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking scale - Self-Report (CHRT-SR)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Concise Health Risk Tracking scale - both CHRT-C and CHRT-SR
Number of subjects: 240
Study: 21733477

Group type: EXPERIMENTAL
Intervention: CAST Clinician Rating (CAST-C)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: CAST Self-Rated (CAST-SR)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 16-item CAST-C
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: 16-item CAST-SR
Number of subjects: 265
Study: 21733483

Group type: EXPERIMENTAL
Intervention: Cognitive inhibition intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 21734313

Group type: EXPERIMENTAL
Intervention: RT3 accelerometers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 21735145

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: axitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: sorafenib-sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: temsirolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: sunitinib-everolimus
Number of subjects: 0
Study: 21736514

Group type: EXPERIMENTAL
Intervention: Nucleus accumbens deep brain stimulation (NAcc-DBS)
Number of subjects: 10
Study: 21737309

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg alteplase
Number of subjects: 103
Study: 21737826

Group type: EXPERIMENTAL
Intervention: 7 days of supervised treadmill and cycling exercise (60 min/day, 60-75% heart rate reserve)
Number of subjects: 11
Study: 21738597

Group type: EXPERIMENTAL
Intervention: Five-drug combination antiretroviral therapy (cART) including enfuvirtide for the first 6 months, optimized cART with three or more drugs for 12 months.
Number of subjects: 28
Study: 21738752

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Allele-specific real-time PCR
Number of subjects: 21
Study: 21740078

Group type: EXPERIMENTAL
Intervention: Fimasartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 21740082

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib in combination with arsenic trioxide, sorafenib, and cytarabine
Number of subjects: 0
Study: 21740673

Group type: EXPERIMENTAL
Intervention: Empiric TB treatment given to 8 (40%) patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline tuberculin skin tests ≥15 mm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lymphocyte proliferative responses to Mycobacterium tuberculosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fever ≥2 weeks plus ≥5 kg weight loss
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Abnormal chest X-rays
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Positive sputum cultures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Median CD4 count
Number of subjects: 20
Study: 21741058

Group type: EXPERIMENTAL
Intervention: Rosiglitazone treatment for 8 weeks
Number of subjects: 7
Study: 21741076

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 231
Study: 21742281

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbal concoctions taken orally for 24 weeks while continuing with Western medical management.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbal concoctions
Number of subjects: 31
Study: 21743336

Group type: EXPERIMENTAL
Intervention: Bonfils intubating fibrescope
Number of subjects: 41
Study: 21744349

Group type: EXPERIMENTAL
Intervention: Low-thermal-injury dissection device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional electrosurgery
Number of subjects: 20
Study: 21744485

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyurea overdose (612 mg/kg body weight)
Number of subjects: 0
Study: 21745716

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antimalarial therapy
Number of subjects: 0
Study: 21746971

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty
Number of subjects: 200
Study: 21746992

Group type: EXPERIMENTAL
Intervention: Combined patching and atropine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21748299

Group type: EXPERIMENTAL
Intervention: Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin and paclitaxel
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Figitumumab
Number of subjects: 19
Study: 21749463

Group type: EXPERIMENTAL
Intervention: Modified epinephrine autoinjector trainer (red safety cap, yellow arrow)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Unmodified epinephrine autoinjector trainer
Number of subjects: 164
Study: 21749641

Group type: EXPERIMENTAL
Intervention: Positive ELISPOT assay
Number of subjects: 312

Group type: COMPARATOR
Intervention: Negative or indeterminate ELISPOT assay
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) treatment
Number of subjects: 312
Study: 21749698

Group type: EXPERIMENTAL
Intervention: Single shot partial breast irradiation (SSPBI)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Polymorphic variant wt XRCC1Arg194Trp
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: mut/het XRCC3Thr241Met
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: wt/het XRCC3A4541G-5'UTR
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: mut/het XRCC1Arg194Trp
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: wt GSTA1
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: wt XRCC1Arg399Gln
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mean dose to whole breast
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: mut/het XRCC1Arg194Trp or wt XRCC3Thr241Met
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: mut/het XRCC1Arg194Trp or wt GSTA1
Number of subjects: 57
Study: 21751289

Group type: EXPERIMENTAL
Intervention: MR elastography (MRE)
Number of subjects: 9
Study: 21752238

Group type: EXPERIMENTAL
Intervention: Carotid ultrasound screening
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Carotid ultrasound screening in men
Number of subjects: 117
Study: 21752239

Group type: EXPERIMENTAL
Intervention: Psychiatric disorders among school dropouts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched control group of regularly enrolled students
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family variables and socioeconomic status
Number of subjects: 0
Study: 21752435

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25mg weekly IV until progression or intolerable toxicity
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 54
Study: 21752743

Group type: EXPERIMENTAL
Intervention: Diet, oral antidiabetes agents, and/or injectables (insulin and/or GLP-1 analogues)
Number of subjects: 5000
Study: 21752947

Group type: EXPERIMENTAL
Intervention: Vero cell antirabies vaccine
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Booster dose after 5 years
Number of subjects: 195
Study: 21754996

Group type: EXPERIMENTAL
Intervention: Early ART (LPV/r+AZT+3TC)
Number of subjects: 17
Study: 21755013

Group type: EXPERIMENTAL
Intervention: High ISG-expressing neutrophils
Number of subjects: 95

Group type: COMPARATOR
Intervention: Normal ISG-expressing neutrophils
Number of subjects: 95
Study: 21756035

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² days 1, 4, 8, 11, 45, 52), cyclophosphamide (50 mg/kg days 15-18), pegfilgrastim (day 20)
Number of subjects: 81
Study: 21756320

Group type: EXPERIMENTAL
Intervention: Structured meal replacements with low glycemic index products and moderately high protein content during breakfast, morning snack, and afternoon snack.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Free living period with habitual ad libitum dietary pattern.
Number of subjects: 17
Study: 21757257

Group type: EXPERIMENTAL
Intervention: Total Body Skin Examination (TBSE)
Number of subjects: 14381
Study: 21757572

Group type: EXPERIMENTAL
Intervention: Women with PAH
Number of subjects: 2969

Group type: COMPARATOR
Intervention: Men with PAH
Number of subjects: 2969
Study: 21757586

Group type: EXPERIMENTAL
Intervention: Bilateral GA
Number of subjects: 193

Group type: COMPARATOR
Intervention: Early/intermediate AMD
Number of subjects: 193

Group type: COMPARATOR
Intervention: Exudative AMD
Number of subjects: 193
Study: 21757630

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desmopressin
Number of subjects: 0
Study: 21757643

Group type: EXPERIMENTAL
Intervention: Intradialytic hypertension
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no intradialytic hypertension)
Number of subjects: 50
Study: 21760564

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Echocardiography criteria
Number of subjects: 252
Study: 21760886

Group type: EXPERIMENTAL
Intervention: pegylated-interferon/ribavirin
Number of subjects: 646
Study: 21761342

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation in castrate mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low serum testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone suppression
Number of subjects: 0
Study: 21762873

Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg, administered orally 30 min before HUT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: L-NAME (1 mg/kg, infused over a 60-min period)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 7
Study: 21763168

Group type: EXPERIMENTAL
Intervention: Medically supervised fasts in children with the c.1436C→T variant
Number of subjects: 5
Study: 21763217

Group type: EXPERIMENTAL
Intervention: Mood-stabilizing medications
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Lower scores on the 'powerful others' dimension of locus of control
Number of subjects: 140

Group type: COMPARATOR
Intervention: BSRI masculinity scores
Number of subjects: 140
Study: 21763653

Group type: EXPERIMENTAL
Intervention: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy (HmG-CoA-reductase inhibitors)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy
Number of subjects: 100
Study: 21764499

Group type: EXPERIMENTAL
Intervention: Rhythm analysis pause during CPR
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Quality of CPR before and after the pause
Number of subjects: 5
Study: 21764815

Group type: EXPERIMENTAL
Intervention: Scheduled in-hospital follow-up of CIEDs
Number of subjects: 3362

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 3362

Group type: EXPERIMENTAL
Intervention: Pacemaker (PM)
Number of subjects: 3362

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 3362

Group type: EXPERIMENTAL
Intervention: Unscheduled visits
Number of subjects: 3362

Group type: EXPERIMENTAL
Intervention: First visits
Number of subjects: 3362
Study: 21765003

Group type: EXPERIMENTAL
Intervention: Food record
Number of subjects: 450

Group type: COMPARATOR
Intervention: Food frequency questionnaire
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 24-hour dietary recalls
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Calibration equations including body mass index, age, and ethnicity
Number of subjects: 450
Study: 21765072

Group type: EXPERIMENTAL
Intervention: Risk factor questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QuantiFERON Gold In-Tube test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-SPOT.TB test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TST
Number of subjects: 0
Study: 21765124

Group type: EXPERIMENTAL
Intervention: Patients with copeptin concentrations in the highest quartile
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Patients with elevated copeptin and hyponatremia
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Patients with elevated copeptin
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 557
Study: 21765864

Group type: EXPERIMENTAL
Intervention: Exercise with behavioral activation strategies (38 classes over 24 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (depression treatment referrals and print information on diabetes management)
Number of subjects: 60
Study: 21767228

Group type: EXPERIMENTAL
Intervention: HIV-infected men
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control men
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with greater visceral AT (VAT)
Number of subjects: 586

Group type: COMPARATOR
Intervention: Control subjects in lowest quartile of leg SAT
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with low leg SAT
Number of subjects: 586
Study: 21767331

Group type: EXPERIMENTAL
Intervention: Crizotinib (PF-02341066)
Number of subjects: 3
Study: 21767595

Group type: EXPERIMENTAL
Intervention: 15-μg dose of a monovalent, unadjuvanted inactivated 2009 H1N1 influenza vaccine
Number of subjects: 148
Study: 21768536

Group type: EXPERIMENTAL
Intervention: Nonapposed side-branch struts
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ISA struts
Number of subjects: 99

Group type: COMPARATOR
Intervention: Well-apposed struts
Number of subjects: 99
Study: 21769849

Group type: EXPERIMENTAL
Intervention: Imatinib (up to 600 mg/day)
Number of subjects: 20
Study: 21771823

Group type: EXPERIMENTAL
Intervention: De novo CRT implantations
Number of subjects: 2367

Group type: COMPARATOR
Intervention: Upgrades to CRT
Number of subjects: 2367

Group type: COMPARATOR
Intervention: Both groups (de novo and upgrades)
Number of subjects: 2367
Study: 21771924

Group type: EXPERIMENTAL
Intervention: OMT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 21771945

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 1159

Group type: COMPARATOR
Intervention: Standard cardiac troponin assay (cTnT)
Number of subjects: 1159
Study: 21772051

Group type: EXPERIMENTAL
Intervention: Elevated tricuspid regurgitant jet velocity (TRV)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Age, splenectomy, hepatitis C, smoking
Number of subjects: 325
Study: 21774578

Group type: EXPERIMENTAL
Intervention: Weekends
Number of subjects: 81
Study: 21774843

Group type: EXPERIMENTAL
Intervention: Nit-Occlud® PDA-R
Number of subjects: 29
Study: 21775114

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 0
Study: 21775497

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 539
Study: 21775510

Group type: EXPERIMENTAL
Intervention: Insulin-resistant women (C-ISI <4.6)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insulin-sensitive women
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Women with impaired glucose tolerance
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups (insulin-resistant and insulin-sensitive)
Number of subjects: 65
Study: 21775836

Group type: EXPERIMENTAL
Intervention: Superficial endometriosis lesions
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Deeply infiltrating lesions
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Endometriomas
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Lesion depth, disease burden, and number of lesions or endometriomas
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chronic pain patients without endometriosis (n = 37)
Number of subjects: 96
Study: 21777076

Group type: EXPERIMENTAL
Intervention: Untreated HIV-infected children
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: CD4 counts above WHO ART-initiation criteria (n=53)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 294
Study: 21777890

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) measurements
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) parameters
Number of subjects: 267
Study: 21778120

Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD) measured at baseline and annually
Number of subjects: 2110

Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD)
Number of subjects: 2110
Study: 21778257

Group type: COMPARATOR
Intervention: Portopulmonary hypertension (PoPH)
Number of subjects: 174
Study: 21778262

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-paced walking
Number of subjects: 12
Study: 21782507

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 395

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 395
Study: 21782771

Group type: EXPERIMENTAL
Intervention: Presence of Mallory-Denk bodies (MDBs) in liver biopsy samples
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Presence of MDBs
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: MDB gain (61 patients, 7.2%)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: MDB loss (101 patients, 12.0%)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Development of MDBs
Number of subjects: 1050
Study: 21784508

Group type: EXPERIMENTAL
Intervention: AVI-4658 (phosphorodiamidate morpholino oligomer) at doses of 0.5, 1.0, 2.0, 4.0, 10.0, and 20.0 mg/kg bodyweight
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AVI-4658 (phosphorodiamidate morpholino oligomer)
Number of subjects: 19
Study: 21784781

Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution (AZLI) thrice daily (AZLI3)
Number of subjects: 274
Study: 21785475

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy continued during interventional techniques
Number of subjects: 3179

Group type: COMPARATOR
Intervention: Antithrombotic therapy discontinued prior to interventional techniques
Number of subjects: 3179

Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 3179
Study: 21787417

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day orally for 4 weeks on treatment, followed by 2 weeks off treatment
Number of subjects: 37